AI Science Tracker
EN

AI-based prognosis and chemotherapy benefit in node-positive, HR+ breast cancer: a blinded external validation on SWOG-8814 trial

Indiana University; Fred Hutchinson Cancer Center; Loyola University Chicago Stritch School of Medicine; Ataraxis AI; University of Alabama at Birmingham; University of Michigan Medical School; Emory University; University of Kansas Medical Center · 23 Oct 2026 · medicine

Discovery

AI-based prognosis and chemotherapy benefit in node-positive, HR+ breast cancer: a blinded external validation on SWOG-8814 trial

Source check: Source checked. Not independent scientific confirmation.

Finding: Results/Abstract: in the multi-modal score, DFS association HR 1.60 (95% CI 1.44–1.78) and C-index 0.66 versus 0.59 for histology-only. Chemotherapy-benefit interaction was exploratory and did not meet conventional significance (p=0.053); only the prognostic result supports approval. This is the result-bearing preprint version dated 2026-10-23; peer-review status is not established by the reviewed source.

Technology: Methods/Abstract: locked Ataraxis Breast CTX scores use H&E whole-slide pathology alone or combined with clinical variables; trial data were not used for retraining and predictions were blinded to outcome.

Publication: Preprint · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Methods/Abstract: locked Ataraxis Breast CTX scores use H&E whole-slide pathology alone or combined with clinical variables; trial data were not used for retraining and predictions were blinded to outcome.
Test and result
Results/Abstract: in the multi-modal score, DFS association HR 1.60 (95% CI 1.44–1.78) and C-index 0.66 versus 0.59 for histology-only. Chemotherapy-benefit interaction was exploratory and did not meet conventional significance (p=0.053); only the prognostic result supports approval. Methods, “Study design and population”: blinded external evaluation in 677 of 1,477 participants from phase III randomized SWOG-8814, with outcome analysis by SWOG; DFS primary endpoint. The 677-sample digitized-slide subset is 46% of trial cohort; not prospective contemporary clinical utility.
Limitation / still unknown
nostic association with DFS in a blinded external randomized-trial cohort; chemotherapy-benefit prediction remains exploratory and unconfirmed.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.medrxiv.org/content/10.64898/2026.10.21.26366092v1.full.pdf · https://www.medrxiv.org/content/10.64898/2026.10.21.26366092v1.full · https://pmc.ncbi.nlm.nih.gov/articles/PMC13738861/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.